Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature-Reference-Cited by-同舟云学术

Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature

Published:2018-11-25 Issue: Volume:2018 Page:1-5
ISSN:1687-9627
Container-title:Case Reports in Medicine
language:en
Short-container-title:Case Reports in Medicine

Author:

Kharel Prakash¹^ORCID,Uprety Deekchha²,Chandra Abhinav B.³,Hu Yirui⁴,Belur Anuradha Avinash⁵,Dhakal Ajay⁶

Affiliation:

1. Department of Hospital Medicine, Geisinger Medical Center, 100 N Academy Ave., Danville, PA 17821, USA

2. Renal Division, Brigham and Women’s Hospital, Boston, MA, USA

3. Yuma Regional Medical Center, Yuma, AZ, USA

4. Center for Health Research, Geisinger Medical Center, 100 N Academy Ave., Danville, PA 17821, USA

5. Multi Care Regional Cancer Center, Auburn, WA, USA

6. Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA

Abstract

Bortezomib, a proteasome inhibitor, is an established therapy against multiple myeloma. Bortezomib-induced lung injury, although not appreciated during the introductory time of the medication, has now been highlighted in multiple case reports. The objective of this study is to report a case of bortezomib-induced lung injury, review current literature, and perform exploratory analysis.

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://downloads.hindawi.com/journals/crim/2018/2913124.pdf

Reference28 articles.

1. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

2. Bortezomib-Related Diffuse Alveolar Hemorrhage

3. Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient

4. Severe pulmonary complication after bortezomib treatment for multiple myeloma

5. Rapid Response to High-Dose Steroids of Severe Bortezomib-Related Pulmonary Complication in Multiple Myeloma

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib Increased Vascular Permeability by Decreasing Cell–Cell Junction Molecules in Human Pulmonary Microvascular Endothelial Cells;International Journal of Molecular Sciences;2023-06-29

2. Pneumonitis associated with bortezomib in a patient with multiple myeloma;Journal of Oncology Pharmacy Practice;2022-12-07

3. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML;Blood Reviews;2022-11

4. Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models;PNAS Nexus;2022-10-11

5. USP10 as a Potential Therapeutic Target in Human Cancers;Genes;2022-05-06